Literature DB >> 22825919

A primer on arrhythmias in patients with hypertrophic cardiomyopathy.

Katy E Bockstall1, Mark S Link.   

Abstract

Patients with hypertrophic cardiomyopathy are at risk of atrial and ventricular arrhythmias, yet treatment options for these patients are made almost solely by extrapolation from patients with other diseases. Heart block may be seen spontaneously but is especially prevalent following septal reduction strategies. Atrial fibrillation is the most common arrhythmia in patients with hypertrophic cardiomyopathy. The onset of atrial fibrillation often represents a turning point clinically for patients, marked by substantial functional deterioration and morbidity. Sudden cardiac death is the most common cause of death in the young patient, but still contributes to mortality in older patients. Major risk factors for sudden cardiac death include resuscitated sudden cardiac death, marked hypertrophy, syncope, and family history of sudden cardiac death due to hypertrophic cardiomyopathy. Minor risk factors for sudden cardiac death include nonsustained ventricular tachycardia, and hypotensive response to exercise. Emerging possible risk factors include atrial fibrillation, myocardial ischemia, left ventricular outflow tract obstruction, genetic mutations, left ventricular apical aneurysms, myocardial fibrosis, and end stage disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22825919     DOI: 10.1007/s11886-012-0297-3

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  95 in total

1.  De subitaneis mortibus. XII. Asymmetrical hypertrophy of the heart.

Authors:  T N James; T K Marshall
Journal:  Circulation       Date:  1975-06       Impact factor: 29.690

2.  Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy.

Authors:  Shikhar Agarwal; E Murat Tuzcu; Milind Y Desai; Nicholas Smedira; Harry M Lever; Bruce W Lytle; Samir R Kapadia
Journal:  J Am Coll Cardiol       Date:  2010-02-23       Impact factor: 24.094

3.  Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy.

Authors:  Perry M Elliott; Juan R Gimeno; María T Tomé; Jaymin Shah; Deirdre Ward; Rajesh Thaman; Jens Mogensen; William J McKenna
Journal:  Eur Heart J       Date:  2006-06-05       Impact factor: 29.983

Review 4.  Implications of arrhythmias and prevention of sudden death in hypertrophic cardiomyopathy.

Authors:  A Selcuk Adabag; Barry J Maron
Journal:  Ann Noninvasive Electrocardiol       Date:  2007-04       Impact factor: 1.468

5.  Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy.

Authors:  Martin S Maron; Evan Appelbaum; Caitlin J Harrigan; Jacki Buros; C Michael Gibson; Connie Hanna; John R Lesser; James E Udelson; Warren J Manning; Barry J Maron
Journal:  Circ Heart Fail       Date:  2008-06-23       Impact factor: 8.790

6.  Hypertrophic cardiomyopathy complicated by severe bradycardias: a pedigree report.

Authors:  Dao Wen Wang; You Bin Deng
Journal:  Clin Cardiol       Date:  2002-02       Impact factor: 2.882

7.  Severe cardiac conduction disturbances and pacemaker implantation in patients with hypertrophic cardiomyopathy.

Authors:  Roberto Barriales-Villa; Raúl Centurión-Inda; Xusto Fernández-Fernández; Martín F Ortiz; Luisa Pérez-Alvarez; Isabel Rodríguez García; Manuel Hermida-Prieto; Lorenzo Monserrat
Journal:  Rev Esp Cardiol       Date:  2010-08       Impact factor: 4.753

8.  Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: impact of age, atrial remodelling, and disease progression.

Authors:  Paolo Di Donna; Iacopo Olivotto; Sara Dalila Luisella Delcrè; Domenico Caponi; Marco Scaglione; Isabelle Nault; Antonio Montefusco; Francesca Girolami; Franco Cecchi; Michel Haissaguerre; Fiorenzo Gaita
Journal:  Europace       Date:  2010-03       Impact factor: 5.214

9.  Myofilament Ca2+ sensitization causes susceptibility to cardiac arrhythmia in mice.

Authors:  Franz Baudenbacher; Tilmann Schober; Jose Renato Pinto; Veniamin Y Sidorov; Fredrick Hilliard; R John Solaro; James D Potter; Björn C Knollmann
Journal:  J Clin Invest       Date:  2008-11-20       Impact factor: 14.808

10.  Syncope and risk of sudden death in hypertrophic cardiomyopathy.

Authors:  Paolo Spirito; Camillo Autore; Claudio Rapezzi; Paola Bernabò; Roberto Badagliacca; Martin S Maron; Sergio Bongioanni; Fabio Coccolo; N A Mark Estes; Caterina S Barillà; Elena Biagini; Giovanni Quarta; Maria Rosa Conte; Paolo Bruzzi; Barry J Maron
Journal:  Circulation       Date:  2009-03-23       Impact factor: 29.690

View more
  3 in total

Review 1.  Myocardial Interstitial Fibrosis in Nonischemic Heart Disease, Part 3/4: JACC Focus Seminar.

Authors:  Javier Díez; Arantxa González; Jason C Kovacic
Journal:  J Am Coll Cardiol       Date:  2020-05-05       Impact factor: 24.094

2.  Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience.

Authors:  Jonathan Weinstock; Yousef H Bader; Martin S Maron; Ethan J Rowin; Mark S Link
Journal:  J Am Heart Assoc       Date:  2016-02-12       Impact factor: 5.501

Review 3.  Treatment of myocardial interstitial fibrosis in pathological myocardial hypertrophy.

Authors:  Fuyu Zhu; Peng Li; Yanhui Sheng
Journal:  Front Pharmacol       Date:  2022-09-30       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.